Oruka Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Oruka Therapeutics with a Buy rating and no price target. Oruka is backed by “sophisticated” monoclonal antibody engineering and both ORKA-001 and ORKA-002 have a high probability of success by targeting the same epitope as Skyrizi/Bimzelx, the analyst tells investors in a research note. The firm says the Oruka story “satisfies investor hunger for accessible yet protected biologics targeting large, established markets.”